Meijboom, KE, Volpato, V, Monzón-Sandoval, J, Hoolachan, JM, Hammond, SM, Abendroth, F, de Jong, OG, Hazell, G, Ahlskog, N, Wood, MJA, Webber, C and Bowerman, M ORCID: (2021) Combining multi-omics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight. (In Press)

[img] Text
Clean Copy - No changes indicated.pdf - Accepted Version
Restricted to Repository staff only

Download (2MB)


Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, proteomics and perturbational datasets. This revealed potential drug candidates for repurposing in SMA. One of the candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including lifespan, weight and key molecular networks in skeletal muscle. Our work highlights the potential of multiple and parallel data driven approaches for the development of novel treatments for use in combination with SMN restoration therapies.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Medicine and Health Sciences > School of Medicine
Depositing User: Symplectic
Date Deposited: 19 May 2021 09:01
Last Modified: 19 May 2021 09:01

Actions (login required)

View Item View Item